Table 3.

Frequency distribution of Chromosome Aberrations (CA) in 500 bone marrow cells examined (100 cells from each individuals).

			Mitotic Index		Chromosome Aberration				Micronucleated Erythrocyte					Sperm Head Anomaly
Intervals (hr)	Drug potency		% ± SE	% of Increased MI.	% of Major CA	% of Other CA	% of Total CA ± SE	% of Prot.	% of MN in NCE	% of MN in PCE	P/N	% of Total MN in NCE & PCE	% of Prot.	% of SHA ± SE	% of prot.
6	30	T5	1.84 ± 0.22		3.4	5.4	8.8 ± 1.14		0.15	0.58	0.11	0.21 ± 0.02		1.6 ± 0.15
		C5	1.42 ± 0.14	0.42	4.4	6	10.4 ± 1.82	1.6	0.31	0.72	0.33	0.41 ± 0.04	0.20a	1.64 ± 0.07	0.04
	200	T6	2.1 ± 0.25		2	3	5 ± 1.17		0.14	0.7	0.24	0.22 ± 0.05		1.72 ± 0.17
		C6	1.48 ± 0.16	0.62	4.2	4.6	10.8 ± 1.14	5.8	0.33	1.06	0.51	0.48 ± 0.05	0.26b	1.5 ± 0.12	-0.22
12	30	T5	2.24 ± 0.12		4.8	6.4	11.2 ± 0.65		0.16	0.59	0.20	0.27 ± 0.02		1.7 ± 0.22
		C5	1.56 ± 0.13	0.68b	8	9.4	17.4 ± 1.68	6.2b	0.43	0.77	0.49	0.55 ± 0.05	0.32c	2.16 ± 0.28	0.46a
	200	T6	2.42 ± 0.12		3	4.8	7.4 ± 0.74		0.14	0.38	0.18	0.17 ± 0.02		1.52 ± 0.19
		C6	1.46 ± 0.13	0.96c	5.8	10.2	16 ± 1.54	8.2c	0.36	0.81	0.45	0.51 ± 0.04	0.34c	2.12 ± 0.21	0.6
24	30	T5	2.04 ± 0.18		6.0	6.6	12.6 ± 1.2		0.31	1	0.31	0.47 ± 0.04		3.02 ± 0.19
		C5	1.1 ± 0.20	0.94b	14.6	15.6	30.2 ± 1.63	17.6c	0.91	1.81	0.32	1.12 ± 0.08	0.77c	5.09 ± 0.30	2.07c
	200	T6	2.28 ± 0.26		4.8	5.6	10.4 ± 1.30		0.18	0.47	0.32	0.25 ± 0.02		2.64 ± 0.23
		C6	0.98 ± 0.17	1.3b	13.4	18.4	31.8 ± 1.55	21.4c	0.87	1.72	0.30	1.05 ± 0.10	0.80c	4.96 ± 0.57	2.32b
48	30	T5	2.44 ± 0.09		5.6	5.8	11.4 ± 1.03		0.36	0.53	0.51	0.41 ± 0.06		3.64 ± 0.29
		C5	1.44 ± 0.20	1b	12.4	13.6	26 ± 1.87	14.6c	0.98	1.63	0.46	1.20 ± 0.04	0.79	5.64 ± 0.34	2b
	200	T6	2.84 ± 0.16		5.0	5.8	10.8 ± 1.14		0.12	0.44	0.55	0.23 ± 0.02		3.38 ± 0.35
		C6	1.16 ± 0.13	1.68c	13.0	14	27 ± 1.11	16.2c	1.06	1.56	0.49	1.22 ± 0.05	0.99c	5.74 ± 0.32	2.36b
72	30	T5	2.86 ± 0.14		3.2	5.6	8.8 ± 1.14		0.7	1.23	0.46	0.89 ± 0.09		4.72 ± 0.23
		C5	1.68 ± 0.09	1.18c	8.0	9.4	17.4 ± 1.51	8.6c	1.21	1.64	0.57	1.38 ± 0.04	0.49c	7.06 ± 0.24	2.34c
	200	T6	3.18 ± 0.28		3.6	4.8	8.4 ± 1.33		0.12	0.55	0.27	0.21 ± 0.04		5.38 ± 0.20
		C6	1.6 ± 0.09	1.58c	9.0	12.4	21.4 ± 1.30	13c	1.45	0.64	0.64	1.38 ± 0.09	1.17c	7.96 ± 0.35	2.58c
96	30	T5	2.68 ± 0.24		3.8	4.8	8.6 ± 0.90		0.27	0.69	0.29	0.37 ± 0.02		2.18 ± 0.15
		C5	1.68 ± 0.13	1.00b	9.2	10	19.2 ± 1.55	10.6c	1.18	1.34	0.46	1.20 ± 0.04	0.83c	4.88 ± 0.30	2.7c
	200	T6	3 ± 0.23		3.6	4.4	8 ± 0.61		0.15	0.29	0.29	0.23 ± 0.02		1.86 ± 0.13
		C6	1.58 ± 0.13	1.42b	9.0	9.8	18.8 ± 1.31	10.8c	1.06	0.45	0.45	1.10 ± 0.07	0.87c	5.02 ± 0.14	3.16c

a = p < 0.05, b = p < 0.01, c = p < 0.001 (significance levels of t-test) Mitotic Indices (MI) in 5000 cells (1000 cells from each individuals), Micronuclei in normochromatic erythrocytes (NCE) and polychromatic erythrocytes (PCE) in 5000 cells (1000 cells from each individuals) and Sperm head-shape abnormality (SHA) in 5000 sperm (1000 sperm from each individuals) at different fixation intervals in CdCl₂ treated mice combined pre- and post-fed with Cad Sulph-30 (T₅) and Cad Sulph-200 (T₆) separately and respective alcohol-30 (C₅) and alcohol-200 (C₆) fed controls.